RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Portfolio Pulse from
Aptevo Therapeutics announced that two additional AML patients achieved remission within 30 days in the RAINIER trial using mipletamig in combination with standard care. Overall, 9 out of 10 patients achieved remission with the triplet combination therapy.
March 20, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics' RAINIER trial shows promising results with 9 out of 10 AML patients achieving remission using mipletamig in combination therapy. This could positively impact APVO's stock as the trial progresses successfully.
The successful remission rates in the RAINIER trial highlight the potential effectiveness of Aptevo's mipletamig, which could lead to increased investor confidence and a positive impact on APVO's stock price. The absence of Cytokine Release Syndrome further supports the safety profile of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100